CASRN: 68786-66-3
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of triclabendazole during breastfeeding. Because of protein binding of 96% to 99% for the drug and metabolites, exposure of the breastfed infant is likely to be low.
Drug Levels
Triclabendazole is metabolized into its active sulfoxide metabolite, which is further metabolized to the active sulfone metabolite. These drugs have half-lives of 8, 14, and 11 hours, respectively.
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Triclabendazole
CAS Registry Number
68786-66-3
Drug Class
Breastfeeding
Lactation
Milk, Human
Anti-Infective Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Publication Details
Publication History
Last Revision: February 15, 2025.
Copyright
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Publisher
National Institute of Child Health and Human Development, Bethesda (MD)
NLM Citation
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Triclabendazole. [Updated 2025 Feb 15].